A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

Last updated: October 7, 2024
Sponsor: Tisento Therapeutics
Overall Status: Terminated

Phase

2

Condition

N/A

Treatment

Placebo

CY6463

Clinical Study ID

NCT04798989
C6463-202
  • Ages > 60
  • All Genders

Study Summary

This study is being conducted to test the safety, tolerability, and pharmacokinetics of the investigational drug CY6463 compared with placebo in individuals who are aged 60 years or older and have Alzheimer's disease (AD) along with common cardiovascular risk factors.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Provide written informed consent prior to the performance of any protocol-specifiedprocedure or, if unable to provide informed consent due to cognitive status,provides assent to participate, with a legally authorized representative (LAR)providing written informed consent on behalf of the participant.

  2. 60 years of age or older

  3. Meets core clinical criteria for probable AD dementia according to the 2011 NationalInstitute on Aging-Alzheimer's Associated guidelines. Can be based on medicalhistory.

  4. Mini-Mental State Examination (MMSE) score of 20 to 26 (inclusive)

  5. Confirmation of AD pathophysiology

  6. At least 2 cardiovascular risk factors per protocol criteria

  7. Magnetic resonance imaging (MRI) scan (existing MRI obtained ≤6 months beforeScreening is acceptable) findings of mild-to-moderate subcortical small-vesseldisease

  8. If receiving concomitant or chronic medication(s), has had no change for ≥4 weeksbefore study drug initiation and has no plans to alter the regimen(s) during thestudy

  9. If male, agrees to refrain from donating sperm from the Screening visit through 90days after taking the final study drug dose

  10. If male, agrees to use protocol-specified, effective contraception methods from thesigning of the informed consent form (ICF) until ≥90 days after taking the finalstudy drug dose.

  11. If female, is postmenopausal/not of reproductive potential defined per protocol

  12. Agrees to the study procedures, including undergoing lumbar puncture forcerebrospinal fluid (CSF) samples

Exclusion

Exclusion Criteria:

  1. Severe visual, auditory, social, or cognitive impairment

  2. Dementia-related disorder other than AD or vascular dementia (eg, Parkinson'sdisease, Huntington's disease, frontotemporal dementia, schizophrenia, Lewy bodydementia)

  3. Symptomatic large-vessel disease, symptomatic carotid artery disease, large vesselinfarcts, or strategic lacunar infarcts or infarcts>15 mm

  4. History of significant central nervous system (CNS) trauma that has affected brainfunction

  5. Low blood pressure (BP), defined as systolic BP ≤90 mmHg or diastolic BP ≤60 mmHg.

  6. Orthostatic hypotension.

  7. Unable to undergo MRI

  8. Unable to undergo lumbar puncture procedure

  9. Unable to participate in electroencephalography (EEG) protocol due to hearingimpairment or inability to tolerate EEG cap or headphones

  10. Uncontrolled or unstable chronic disease

  11. Kidney impairment requiring dialysis; history of renal transplant

  12. Needs continuous direct medical care and nursing supervision.

  13. Family history of short QT syndrome or long QT syndrome

  14. Clinically significant cardiac involvement

  15. History of cancer. Exceptions: localized cutaneous basal or squamous cell carcinomain the last 5 years, low-grade localized prostate/cervical cancers, or previouslocalized prostate/cervical cancers that have a low likelihood of recurrence

  16. Is not suited for study participation in the clinical judgment of the investigator

Additional inclusion and exclusion criteria apply, per protocol.

Study Design

Total Participants: 12
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2
Study Start date:
November 02, 2021
Estimated Completion Date:
November 28, 2022

Study Description

CY6463 is an investigational drug being developed as a symptomatic and potentially disease-modifying therapy for Alzheimer's disease (AD) and other serious central nervous system disorders. As a soluble guanylate cyclase (sGC) stimulator, CY6463 can cross the blood-brain barrier and boosts the activity of the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway. This signaling pathway is important in many aspects of brain health, including in the control of blood flow in the brain, how brain cells use energy, and how those cells communicate with one another. Impairment of this pathway is a critical part of the origin of many neurodegenerative diseases that can cause a loss of brain function including memory and decision-making abilities. There are clear links between disrupted NO signaling and impaired brain function in patients with AD and vascular pathology (ADv). ("Vascular pathology" refers to abnormalities of the blood vessels that are more likely to occur when a person has cardiovascular risk factors like high blood pressure, diabetes, and/or obesity.) It is hypothesized that CY6463 may help patients with ADv maintain or recover some of their original cognitive function.

In this study, participants will be randomized to receive approximately 87 sequential days (~3 months) of study drug (CY6463 or placebo) once daily (QD) and will complete 7 scheduled site visits over the course of the study, from Screening through Follow up.

Connect with a study center

  • Clinical Endpoints

    Scottsdale, Arizona 85258
    United States

    Site Not Available

  • Optimus U Corp

    Miami, Florida 33125
    United States

    Site Not Available

  • Synexus Clinical Research US, Inc. - The Villages

    The Villages, Florida 32162
    United States

    Site Not Available

  • Hawaii Pacific Neurosciences, LLC

    Honolulu, Hawaii 96817
    United States

    Site Not Available

  • University of Kentucky

    Lexington, Kentucky 40536
    United States

    Site Not Available

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.